Pitt Researchers Identify Two-Mutation Combo That Gives Melanoma Cells Indefinite Lifespan

Scientists at the University of Pittsburgh School of Medicine have filled in a two-decade gap in the biology of melanoma: why the skin cancer's cells keep dividing long after normal cells would shut down.

The finding turns on telomeres, the protective caps at the ends of chromosomes. Every time a cell divides, those caps shorten a little. Cancer cells get around this limit by reactivating telomerase, the enzyme that rebuilds them. In melanoma, that reactivation usually runs through mutations in a gene called TERT. The problem is, TERT mutations alone have never been enough to explain the picture researchers actually see in patients.

As reported in a paper published in Science and summarized by the University of Pittsburgh on June 30, 2026, <cite index="10-7,10-8,10-9">roughly 75% of melanoma tumors carry TERT mutations that increase telomerase production and activity, yet even after researchers introduced those mutations into melanocytes in the lab, they still could not recreate the unusually long telomeres found in melanoma tumors.</cite> Something was missing.

The missing piece turned out to be a second gene. <cite index="17-6,17-7,17-8">The breakthrough came when Pattra Chun-on, M.D., a Ph.D. student in Jonathan Alder's lab, focused on a gene called ACD, which produces a telomere-binding protein known as TPP1. TPP1 is part of the shelterin complex, a group of proteins that protects telomeres and controls access to them, and one of TPP1's jobs is recruiting telomerase to chromosome ends.</cite>

What Chun-on found in the mutation databases was a cluster of recurring variants in the ACD promoter region -- and they looked familiar. <cite index="22-5,22-6">Those promoter mutations created a transcription factor binding site similar to mutations previously identified in the TERT gene promoter, and co-expression of TERT and TPP1 leads to synergistic telomere lengthening.</cite>

<cite index="17-10,17-11,17-12,17-13">In effect, melanoma cells had evolved a two-part strategy: one mutation increased telomerase production through TERT, while the other improved the cell's ability to bring telomerase directly to telomeres through TPP1. Together, the effects were far stronger than either mutation alone, and when the researchers introduced both mutated genes into cells, telomeres lengthened dramatically, closely matching the unusually long telomeres seen in melanoma tumors.</cite>

The prevalence figures here matter for context. <cite index="22-8,22-9,22-11">TERT promoter mutations appear in about 75% of melanomas but are not sufficient to maintain telomeres on their own; the newly identified ACD promoter variants are present in about 5% of cutaneous melanoma and co-occur with TERT promoter mutations.</cite> That 5% figure is not nothing -- melanoma is one of the fastest-rising cancers by incidence -- but it also means the two-hit model applies to a specific subset of patients, not the full population. The paper does not address whether ACD variants are found in the 25% of melanomas that lack TERT mutations.

The translational argument is straightforward on paper. <cite index="23-4,23-5">This discovery has changed the way scientists understand the onset of melanoma, and by identifying a telomere maintenance system that is unique to cancer, scientists have a new target for treatments.</cite> Whether that target is druggable -- and at what cost to normal cells that also depend on the shelterin complex -- is the next question the paper doesn't answer. TPP1 is not exclusive to cancer; disrupting it in healthy tissue carries real theoretical risks.

The research is also worth reading with a note on timing. The paper in *Science* carries a 2022 publication date, and the University of Pittsburgh appears to have issued fresh communications summarizing the work in late June 2026. The underlying molecular biology hasn't changed, but the renewed institutional spotlight suggests ongoing follow-up work the team hasn't yet published.

The senior author is Jonathan Alder, Ph.D., assistant professor in the Division of Pulmonary, Allergy, and Critical Care Medicine at Pitt's School of Medicine. The paper is freely available via Science's open-access provisions.

Sources cited:
- Science (Chun-on et al., DOI: 10.1126/science.abq0607) (https://www.science.org/doi/10.1126/science.abq0607)
- ScienceDaily / University of Pittsburgh press summary, June 30 2026 (https://www.sciencedaily.com/releases/2026/06/260625014833.htm)
- SciTechDaily coverage (https://scitechdaily.com/cancer-mystery-solved-scientists-discover-how-melanoma-becomes-immortal/)